CST has an independently developed antibody production platform, covering phosphorylated antibodies, flow cytometry antibodies, immunoassay kits, and multiplex detection technologies, which are widely used in basic research, drug development, and clinical diagnosis. The company has established a comprehensive antibody validation system (such as PASS) ™ Verify technology to ensure high specificity and repeatability of the product. CST also provides customized services and automated testing solutions, maintaining long-term partnerships with top academic institutions such as Harvard and Stanford, as well as pharmaceutical companies such as Merck and Novartis, to promote breakthroughs in biomedical research.

In recent years, CST has continued to expand its product line, launching cutting-edge technology reagents such as single-cell analysis and spatial genomics, and accelerating its layout in the accompanying diagnostic market. In 2023, the company announced cooperation with multiple biopharmaceutical companies to develop tumor immunotherapy related testing solutions, while strengthening market expansion in the Asia Pacific region. CST continues to operate privately, with steady annual revenue growth. In the future, it plans to further integrate AI and automation technologies to improve antibody development and detection efficiency, and consolidate its global leadership position in the field of scientific reagents.